Myeloma-associated renal disorders are rare events among renal transplants and can occur as recurrent or de novo disease. We describe an unusual case of renal allograft dysfunction due to myeloma cast nephropathy occurring 19 years after having received a renal transplant in a patient with no prior history of multiple myeloma or monoclonal gammopathy preceding transplantation. Our patient was treated with five cycles of chemotheraphy(bortezomib, melphalan and steroids), which resulted in short-term improvement in allograft dysfunction and complete haematological remission. The longer patient and graft survival after renal transplantation make post-transplant lymphoproliferative disease more frequent. Multiple myeloma after kidney transpl...
Abstract Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly popular treatmen...
Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients ...
Registry data show that there is an overall 3–5-fold increase in cancer risk in transplant recipient...
International audienceBackground: The increased survival of patients with multiple myeloma (MM) rais...
Acute renal failure is a frequent feature in patients with multiple myeloma (MM). MM-related renal i...
A patient with plasma cell myeloma presented in severe renal failure but was otherwise considered a ...
The introduction of several novel therapeutic agents has improved the outcome in multiple myeloma (M...
multiple myeloma, revealed by a nephrotic syndrome and kidney failure. 1CHU Nancy-Brabois – Service ...
International audiencePost-transplantation lymphoproliferative disorder (PTLD) is a well-know compli...
AbstractBackgroundMyeloid sarcoma is well described and known in clinical practice, however, it is a...
Light chain-associated kidney compromise is frequent in patients with monoclonal gammopathies; it af...
RATIONALE & OBJECTIVES: Posttransplantation membranous nephropathy (MN) represents a rare complicati...
Introduction: Malignancy management in renal transplant recipients is becoming a major factor affect...
Background and Objectives: Hematopoietic cell transplantation is a common treatment option for a var...
Malignancy is the third major cause of death among transplant recipients. Patient and kidney transpl...
Abstract Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly popular treatmen...
Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients ...
Registry data show that there is an overall 3–5-fold increase in cancer risk in transplant recipient...
International audienceBackground: The increased survival of patients with multiple myeloma (MM) rais...
Acute renal failure is a frequent feature in patients with multiple myeloma (MM). MM-related renal i...
A patient with plasma cell myeloma presented in severe renal failure but was otherwise considered a ...
The introduction of several novel therapeutic agents has improved the outcome in multiple myeloma (M...
multiple myeloma, revealed by a nephrotic syndrome and kidney failure. 1CHU Nancy-Brabois – Service ...
International audiencePost-transplantation lymphoproliferative disorder (PTLD) is a well-know compli...
AbstractBackgroundMyeloid sarcoma is well described and known in clinical practice, however, it is a...
Light chain-associated kidney compromise is frequent in patients with monoclonal gammopathies; it af...
RATIONALE & OBJECTIVES: Posttransplantation membranous nephropathy (MN) represents a rare complicati...
Introduction: Malignancy management in renal transplant recipients is becoming a major factor affect...
Background and Objectives: Hematopoietic cell transplantation is a common treatment option for a var...
Malignancy is the third major cause of death among transplant recipients. Patient and kidney transpl...
Abstract Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly popular treatmen...
Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients ...
Registry data show that there is an overall 3–5-fold increase in cancer risk in transplant recipient...